about
Insights from CURE: using clopidogrel on top of standard therapyPrediction of Heart Failure Decompensation Events by Trend Analysis of Telemonitoring Data.Expert knowledge integration in the data mining process with application to cardiovascular risk assessment.Assessment of cardiovascular risk based on a data-driven knowledge discovery approach.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialThrombolytic therapy for women in myocardial infarction. Different prognosis?Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Fibrinolytic therapy an ongoing research field.Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry.Cardiovascular risk and status assessment.Portuguese Registry of Acute Coronary Syndromes: seven years of activity.New approaches for improving cardiovascular risk assessment.Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.Integration of Different Risk Assessment Tools to Improve Stratification of Patients with Coronary Artery Disease.Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.[Guidelines on the management of stable angina pectoris; the experts of the European Society of Cardiology on the management of stable angina pectoris].Cardiovascular disease risk assessment innovative approaches developed in HeartCycle project.Aortic pulse wave velocity and HeartSCORE: improving cardiovascular risk stratification. a sub-analysis of the EDIVA (Estudo de DIstensibilidade VAscular) project.Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Wo2017 Guidelines for Arterial Hypertension Management in Primary Health Care in Portuguese Language Countries.Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry.2017 Guidelines for the management of arterial hypertension in primary health care in Portuguese-speaking countries.Gerbode defect and multivalvular dysfunction: Complex complications in adult congenital heart disease.Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.
P50
Q28192204-3DC7D54D-DE5D-4C42-8BCD-6C50F067CC46Q30854671-78AE21E8-FBA4-40E1-8DFA-4AC8E0F0AD7FQ31035359-3D10DA1A-9DA8-42CB-B112-1E759D7E4681Q31035464-60CA167A-C7D5-4FA4-91FC-BE9D9D93173CQ33755410-07AFEF44-595E-4BB7-BD07-D2F12011FF50Q33780425-33269AB1-A70C-4DB3-BD67-C043C1EA0BD0Q33788973-CC395CA0-AF38-4D7E-9049-8F06F48641B5Q34276182-E2E019C4-D58C-4778-B8A2-365D190E7376Q34631888-2FD25D38-FE89-4FDA-BA8D-D16D884ACA34Q35051753-6D23F47D-A962-4909-88DF-547CC79693AFQ35195203-8A38A24F-D532-4987-870E-C0BB92838408Q35572159-B2ED9EE5-A676-472D-B63B-4C06BE9A8BD6Q36874702-E4BFFC6E-D161-4D30-988C-3C06F62E517EQ38189331-9D65EE4E-A62E-4081-BD8F-13B972DBACD4Q38230675-4B7B7751-2D25-4CA1-89D3-88192418BC1EQ38400558-5466E113-0E06-43EB-A9E1-E95F932C543FQ38458638-1C5468BB-2296-4D14-B3BC-F86E0C080B1BQ38471901-09E532A4-D9D3-4D8E-A63C-116E58E111C5Q38545163-2BC3BB4C-6F25-4963-8BB3-B075CC5B0DB4Q38671637-2BFA25F8-89FE-40E5-B9B4-5993B7DF8A8BQ38773697-3585457E-8D47-4B77-BC81-C492E58FBBBEQ38948558-433A843F-B8CB-440B-A34F-A1AF6443E6AEQ39814698-BC0A6BAC-FFA2-4E3D-A6E2-1E402BF94D23Q39890412-8877557F-9E80-46C1-8204-D9743E6B3E28Q40135622-4ECDE0B3-A1D5-4826-9CCD-A124E6A470C8Q40478828-9478C752-6D6C-4BA1-9ACE-538F66312D33Q40690968-89B8F53C-E4F6-420F-927A-4E896D9F2B6EQ40801986-05FE5775-72F9-4441-BFD8-E8F85390F189Q40886109-7A87B435-8012-474F-85FE-B7DEA57BCCD2Q41745572-94FF4CDC-7404-4197-AC2F-0C4BD33E7AE1Q42877509-04A3443F-BA30-4B66-B320-3334E9C2E0CBQ43451841-3442D98C-B055-4109-85DE-766D47A448B4Q44474646-2D0F7272-EE03-4470-AD06-D0D829120231Q45533771-A7286651-7F59-461E-99DF-38FBC75C6217Q46471441-0C838C5F-438F-493D-A025-6D40AA8FBB42Q47142383-5B3305C1-77BD-4F41-8DD1-03A8863BD0BEQ47261452-BD9598C3-6905-4DEE-8EFA-68D37CB3EEF1Q47604354-5364E663-1F4B-4325-9298-5196973066F8Q48127897-E63045B6-849B-45F2-9EAA-1E61077670F9Q48647701-014358AD-13FC-4E9C-AA40-E8EBE1525F5E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joao Morais
@ast
Joao Morais
@en
Joao Morais
@es
Joao Morais
@nl
Joao Morais
@sl
type
label
Joao Morais
@ast
Joao Morais
@en
Joao Morais
@es
Joao Morais
@nl
Joao Morais
@sl
prefLabel
Joao Morais
@ast
Joao Morais
@en
Joao Morais
@es
Joao Morais
@nl
Joao Morais
@sl
P106
P21
P31
P496
0000-0003-3406-2878
P569
2000-01-01T00:00:00Z